Agennix(德国)

Agennix

美国Agennixwww.agennix.comGPCBiotechAG(NASDAQ:GPCB)和Agennix于2009年2月18号签订商业合并协议AgennixAGisabiopharmaceuticalcompanyresultingfromthecombinationofGPCBiotechAGandAgennixIncorporatedinNovember2009.Weseektoha veameaningfulimpactonthelengthandqualityoflivesofcancerpatientsinareasofmajorunmetmedicalneedbydeveloping,andobtainingapprovalfor,noveloncologytherapies.Ourmostadvancedprogramistalactoferrin,anoraltargetedtherapythatisinPhase3clinicaltrialsinnon-smallcelllungcancer.Additionalclinicaltrialswithtalactoferrinincancerindicationsareplanned,includingkidneycancer,forwhichPhase2dataareavailable.OurotherclinicaldevelopmentprogramsincludeRGB-286638,amulti-targetedkinaseinhibitorinPhase1testing;theoralplatinum-basedcompoundsatraplatin;andatopicalgelformoftalactoferrinforwoundhealing.Weareatransatlanticcompanywithsitesin